Stockscreener 앱 받기
0.6666
7.78%
0.0481
시간 외 거래:
.69
0.0234
+3.51%
Elevation Oncology Inc 주식(ELEV)의 최신 뉴스
Barclays PLC Has $43,000 Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Elevation Oncology (NASDAQ:ELEV) Announces Program Updates and MilestonesOn January 13, 2025, Elevation Oncology, Inc. disclosed in a press release certain developments and upcoming milestones that are set to shape its trajectory in the coming mo - Defense World
Q4 Earnings Forecast for ELEV Issued By William Blair - Defense World
Esophageal Cancer Pipeline Assessment 2024: Therapies, Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Oncolys BioPharma Inc, Genentech, OncoTherapy - The Globe and Mail
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Lelezard
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
Elevation Oncology advances gastric cancer trial, eyes new data in 2025 By Investing.com - Investing.com South Africa
Elevation Oncology advances gastric cancer trial, eyes new data in 2025 - Investing.com India
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones - PR Newswire
Geode Capital Management LLC Increases Position in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Elevation Oncology, Inc. (NASDAQ:ELEV) Shares Bought by Barclays PLC - Defense World
Why Elevation Oncology (ELEV) Is Among the Best Penny Stocks to Invest In According to Media? - Yahoo Finance
Analysts Set Elevation Oncology, Inc. (NASDAQ:ELEV) Price Target at $7.20 - Defense World
Elevation Oncology initiated with an Outperform at William Blair - MSN
Elevation Oncology, Inc. (NASDAQ:ELEV) Stock Position Boosted by State Street Corp - Defense World
Elevation Oncology (NASDAQ:ELEV) Now Covered by William Blair - Defense World
William Blair Initiates Coverage of Elevation Oncology (ELEV) with Outperform Recommendation - MSN
Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise - Benzinga
This Denali Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Friday - Benzinga
Items Tagged with 'ESMO IO 2024' - BioWorld Online
HC Wainwright Reiterates “Buy” Rating for Elevation Oncology (NASDAQ:ELEV) - Defense World
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 - The Eastern Progress Online
Elevation Oncology nominates HER3 ADC as development candidate - BioWorld Online
Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion - ShareCast
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference - The Eastern Progress Online
Elevation Oncology Inc licences Synaffix BV’s ADC platform - European Biotechnology News
Synaffix out-licenses ADC technology to Elevation Oncology - The Pharma Letter
Elevation Oncology selects EO-1022 as HER3 ADC candidate - Investing.com
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors - PR Newswire
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024 - PR Newswire
Elevation Oncology Shares Tumble 39% On $50 Mln Stock-And-Warran… - Marketscreener.com
ELEVElevation Oncology, Inc. Latest Stock News & Market Updates - StockTitan
Five things for pharma marketers to know for Friday morning - MM+M Online
433,545 Shares in Elevation Oncology, Inc. (NASDAQ:ELEV) Bought by GSA Capital Partners LLP - Defense World
Logos Global Management LP Adjusts Stake in Elevation Oncology I - GuruFocus.com
OrbiMed Advisors LLC Increases Stake in Elevation Oncology Inc - GuruFocus.com
Biotechnology Value Fund L P's Strategic Acquisition in Elevatio - GuruFocus.com
Elevation Oncology's SWOT analysis: promising ADC stock faces key data readout - Investing.com
Goldman Sachs Group Inc's Strategic Acquisition in Elevation Onc - GuruFocus.com
Elevation Oncology’s Q3 2024 Highlights and Financial Report - TipRanks
Elevation Oncology's Cancer Drug Shows 43% Response Rate, Secures FDA Fast Track | ELEV Stock News - StockTitan
Ovarian Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Vanguard Group Inc's Strategic Acquisition in Elevation Oncology Inc - GuruFocus.com
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down - Zacks Investment Research
5.49%
0.79%
자본화:
|
볼륨(24시간):